+

WO2024118019A1 - Formulations de gel thermosensibles dermiques pour le traitement d'un oedème lié à une inflammation et de diverses douleurs - Google Patents

Formulations de gel thermosensibles dermiques pour le traitement d'un oedème lié à une inflammation et de diverses douleurs Download PDF

Info

Publication number
WO2024118019A1
WO2024118019A1 PCT/TR2023/051159 TR2023051159W WO2024118019A1 WO 2024118019 A1 WO2024118019 A1 WO 2024118019A1 TR 2023051159 W TR2023051159 W TR 2023051159W WO 2024118019 A1 WO2024118019 A1 WO 2024118019A1
Authority
WO
WIPO (PCT)
Prior art keywords
chitosan
gel formulation
formulation according
polymer
weight
Prior art date
Application number
PCT/TR2023/051159
Other languages
English (en)
Inventor
Muhammet Davut Arpa
Ebrar Elif KESMEN
Original Assignee
Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/018327 external-priority patent/TR2022018327A1/tr
Application filed by Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi filed Critical Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi
Publication of WO2024118019A1 publication Critical patent/WO2024118019A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • the invention relates to sprayable dermal thermosensitive gel formulations developed for the treatment of inflammation-related edema and various pains.
  • Benzydamine is a non-steroidal anti-inflammatory with analgesic, antiseptic and antimicrobial effects, which is often used locally in the treatment of oral diseases such as oral mucositis and mouth ulcers.
  • Benzydamine offers significant advantages in the prevention and treatment of mucositis topically as it inhibits the production of TNF-a. Benzydamine not only stops the progression of mucositis severity but also reduces the intensity of pain.
  • Benzydamine is generally used alone or in combination with various active ingredients as a spray or mouthwash at very low concentrations such as 0.15% in the treatment of oral infections.
  • benzydamine hydrochloride is also used topically on the skin to eliminate various painful conditions such as edema, inflammation and sprain, bruising, and lumbago due to soft tissue injuries caused by various reasons such as surgery and trauma.
  • These products which are generally used commercially in the form of semi-solid gel and cream containing benzydamine at concentrations of 3-5%, are applied 2-3 times a day depending on the condition of the disease.
  • Gels are the formulations that provide higher patient. -compliance than semi-solid oil-based formulations such as creams and ointments.
  • semi-solid formulations also have problems in terms of patient compliance, such as not spreading comfortably to the application area, the amount applied depending on eyeball estimate (apply in the size of a chickpea grain, etc.).
  • in situ gel formulations have started to be developed to overcome such problems. These systems, which gel in situ, are liquid at room temperature or at the temperature where they are stored, and they gel depending on the temperature, pH, or ionic activation in the area where they are applied. Therefore, these systems are more easily applicable formulations because they are in liquid form during application. The fact that they can be sprayed makes them frequently preferred in the pharmaceutical industry in recent years.
  • thermosensitive gels Temperature-sensitive in situ gels are called thermosensitive gels. These systems are dosage forms that gel when they come into contact with the body. Sprayable thermosensitive gel formulations should generally be gellable between 28-34°C, at the same time their viscosity at storage temperature is generally expected to be less than 350 mPa.s. Poloxamers are the most commonly used polymers in the preparation of thermosensitive gels. Poloxamers are polyethylene oxide - polypropylene oxide - polyethylene oxide (PEO-PPO-PEO) triblock copolymers that can dissolve in an aqueous medium to form clear gels. Their high water content has a positive effect on drug absorption, and they are also biocompatible and have low toxicity.
  • PEO-PPO-PEO polyethylene oxide - polypropylene oxide - polyethylene oxide
  • Poloxamer 407 is one of the poloxamers with high solubility capacity consisting of 70% POE and 30% PPO
  • Poloxamer 188 is one of the emulsifiers, dispersing agents, and wetting agents consisting of 80% POE and 20% PPO and is used to increase the bioavailability of low solubility active ingredients.
  • These synthetic polymers with non-ionic properties can interact with hydrophobic surfaces and biological membranes due to their amphiphilic properties.
  • Semi-solid dosage forms such as gels, creams, ointments, and oral formulations containing the same active ingredients, which contain nonsteroidal anti-inflammatory agents and are used topically on application, are frequently used to relieve inflammation-related edema and various pains.
  • Active ingredients such as naproxen sodium, metamizole, and benzydamine hydrochloride are compounds used for this purpose.
  • Benzydamine hydrochloride has 3-5% products commercially available in gel, and cream form prepared using various polymers.
  • disadvantages such as transferring the gel, and cream formulations from the tube, not distributing them widely or evenly over the application surface in a desired manner, or the dose of the application depending on the patient's rule of thumb or eyeball estimate.
  • cream formulations are oil-based, they generally have disadvantages such as lower skin permeability and lower patient compliance than gels.
  • EP2689774B1 relates to a thermo-reversible hydrogel composition
  • a thermo-reversible hydrogel composition comprising a water-soluble block copolymer and gelling agent.
  • the document in question contains a formulation containing 3% benzydamine- but does not mention a sprayable, bioadhesive, and thermosensitive formulation for dermal application.
  • the present invention is in the form of temperature-sensitive (thermosensitive) and sprayable gel formulations containing benzydamine hydrochloride to be used for the relief of problems and pain such as various sprains, dents, inflammatory edema, etc.
  • Sprayable in situ gel formulations allow a standard dose to be applied to the spray head in one press/application. Therefore, the administered dose does not differ from person to person or between per application.
  • the gel formulation can be sprayed at room temperature (20-25°C) as it has a low viscosity (100-350 mPa.s). This is not the case for traditional gels and creams.
  • thermosensitive sprayable formulations When thermosensitive sprayable formulations are sprayed, they spread more easily to a large area and are gelled by the effect of body temperature (37°C) when it comes into contact with the body. While their easy flow provides ease of application, their water-based nature enables superiority over ointments and creams in terms of passing through the skin such as a gel.
  • temperature-sensitive (thermosensitive) sprayable gel formulations containing benzydamine hydrochloride were obtained to be used for the elimination of problems and pain such as sprain, bruise, inflammation-related edema, etc. in order to eliminate the existing disadvantages of semi-solid formulations in terms of application.
  • hydroxypropyl methyl-cellulose which is a cellulose derivative, is also used.
  • Cellulose-derived polymers are used in many different drug delivery systems such as gel and film due to their bioadhesive effects.
  • Bioadhesive polymers adhere to the area where they are applied and ensure that the drug formulation stays in that area for a longer time. Thus, they can improve the bioavailability of the active ingredient by increasing the duration of action of the drug.
  • its permeability-enhancing properties provide an advantage in terms of bioavailability.
  • Non-ionic hydroxypropyl methyl -cellulose provides both bio-adhesive properties and contributes to the structural integrity of the thermosensitive gel.
  • this semi -synthetic polymer is biocompatible and biodegradable. Hydroxypropyl methyl-cellulose is also preferred in the preparation of systems due to its sol-gel effect.
  • the invention offers significant advantages in terms of ease of application and use compared to gel formulations containing benzydamine hydrochloride in the art:
  • -It is in sprayable form, and it is an important advantage that it is in sprayable form, in addition, not all in situ gels/thermosensitive gels are sprayable, for this, the viscosity of the formulation must be at certain intervals.
  • poloxamers that provide thermosensitive properties and polymers with bioadhesive properties in the gel formulation of the invention.
  • Sprayable thermosensitive gel formulation containing benzydamine hydrochloride characterized in that it comprises the following:
  • Benzydamine hydrochloride in the amount of 2-10% by weight as active ingredient, Non-ionic or cationic polymer in the rate of 0.05-20% by weight as bioadhesive polymer,
  • Poloxamer 407 a water-soluble triblock copolymer comprising 70% of unit a and 30% of unit b, represented by the general formula HO-(EO) a (PO)b(EO) a -H at a ratio of 10- 28% by weight as a thermosensitive polymer,
  • Poloxamer 188 water-soluble triblock copolymer, represented by the general formula HO-(EO) a (PO)b(EO) a -H at a rate of 1-20% by weight as a thermosensitive polymer, wherein the unit a comprises 80% and the unit b comprises 20%, Optionally, moisturizing agent in the ratio of 1-10% by weight, Optionally, desired amount of fragrance agent,
  • Benzydamine may exhibit toxic effects if used in doses of more than 10%, as well as disrupting the structure of the formulation.
  • Poloxamers and HPMC provide a sol-gel, that is, a thermosensitive effect, and HPMC also has a bioadhesive feature.
  • Jasmine essence, peppermint essence, lavender essence, and the like can be preferred as scenting agents.
  • the moisturizing agent may be selected from the group comprising glycerin, sorbitol, propylene glycol, polyethylene glycol, and butylene glycol.
  • a non-ionic polymer is a cellulose-derived polymer.
  • the cellulose-derived polymer is hydroxypropyl methyl cellulose or hydroxyethyl cellulose.
  • Cationic polymer is chitosan or its derivatives.
  • Chitosan is preferably dissolved in an organic acid selected from the group of acetic acid, hydrochloric acid, glutamic acid, citric acid, aspartic acid, and lactic acid.
  • Water-soluble thiolate chitosan, chitosan salt or chitosan alkyl ammonium can be used as chitosan derivatives.
  • Chitosan glutamate, chitosan chloride, chitosan lactate, chitosan citrate, chitosan acetate or chitosan aspartate can be used as chitosan salt.
  • Method of preparing the gel formulation of the invention comprising the following process steps: a) Completely dissolving Pol oxamer 407 and Pol oxamer 188, which are polyethylene oxide-polypropylene oxide-polyethylene oxide (PEO-PPO-PEO) copolymers, in a calculated amount of distilled water, b) Keeping the prepared solution in the refrigerator at 2-8°C for 24-48 hours, c) On the other hand, dissolving hydroxypropyl methylcellulose (HPMC) in the remaining part of the distilled water by stirring at 20-25°C for 4-12 hours, d) Combining the HPMC solution and the solution containing the poloxamers by stirring at 20-25°C on a stirrer, e) Adding the active ingredient benzydamine hydrochloride to the solution container and mixing at 200-500 rpm for 1-3 hours.
  • Pol oxamer 407 and Pol oxamer 188 which are polyethylene oxide-polypropylene oxide-
  • glycerin is optionally added as a moisturizing agent and mixed at 200-500 rpm for 30 minutes-2 hours at room temperature and optionally homogenized by adding a fragrance agent.
  • the dissolution in step a continues until the polymers dissolve by stirring at low speed (300 rpm) in the cold-water bath for about 2 hours.
  • Viscosity analyses are of great importance in terms of the applicability and sprayability of in situ gels.
  • viscosity analyses of the formulations developed in Brookfield DV2T RV viscometer were performed. Analyses were carried out at 25°C.
  • Gelation temperature analyzes were performed on a magnetic heating stirrer. In situ gels stored at +4°C were taken from the refrigerator and started to be stirred at 300 rpm on a magnetic heating stirrer in a beaker. The temperature of the device was increased by 2°C per minute to determine the temperature at which the sol formulation began to gel. The temperature value at the time when the magnetic stirrer rod in the beaker stopped was recorded as the gelling temperature of the formulation. Table 1 shows the findings of viscosity and gelling temperature. pH analyses were carried out at 25°C. The pH values of the formulations were determined by immersing the probe of the pH meter in the in-situ gel. The pH values of the developed formulations are generally expected to be between 4 and 6 in order to be compatible with the body. The pH values of the formulations were found to be between 5.5 and 5.9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une formulation de gel thermosensible dermique pulvérisable développée pour le traitement d'un oedème lié à une inflammation et de diverses douleurs et comprend entre 2 et 10 % de chlorhydrate de benzydamine en poids, entre 0,05 et 20 % de polymère bioadhésif en poids, entre 10 et 28 % de poloxamère 407 ou entre 1 et 20 % de poloxamère 188 en tant que polymère thermosensible et une quantité d'eau distillée en poids suffisante pour atteindre 100 % du poids total de la formulation.
PCT/TR2023/051159 2022-12-01 2023-10-18 Formulations de gel thermosensibles dermiques pour le traitement d'un oedème lié à une inflammation et de diverses douleurs WO2024118019A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022018327 2022-12-01
TR2022/018327 TR2022018327A1 (tr) 2022-12-01 Enflamasyona bağli ödem ve çeşi̇tli̇ ağrilarin tedavi̇si̇ i̇çi̇n dermal termosensitiv jel formülasyonlari

Publications (1)

Publication Number Publication Date
WO2024118019A1 true WO2024118019A1 (fr) 2024-06-06

Family

ID=91324608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/051159 WO2024118019A1 (fr) 2022-12-01 2023-10-18 Formulations de gel thermosensibles dermiques pour le traitement d'un oedème lié à une inflammation et de diverses douleurs

Country Status (1)

Country Link
WO (1) WO2024118019A1 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALBERTINI, B. ; PASSERINI, N. ; DI SABATINO, M. ; MONTI, D. ; BURGALASSI, S. ; CHETONI, P. ; RODRIGUEZ, L.: "Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: Formulation, manufacturing and characterization", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 399, no. 1-2, 31 October 2010 (2010-10-31), NL , pages 71 - 79, XP027298456, ISSN: 0378-5173 *
PAGANO CINZIA; GIOVAGNOLI STEFANO; PERIOLI LUANA; TIRALTI MARIA CRISTINA; RICCI MAURIZIO: "Development and characterization of mucoadhesive-thermoresponsive gels for the treatment of oral mucosa diseases", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER AMSTERDAM, NL, vol. 142, 1 November 2019 (2019-11-01), NL , XP085955837, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2019.105125 *
ROSSI, S. ; MARCIELLO, M. ; BONFERONI, M.C. ; FERRARI, F. ; SANDRI, G. ; DACARRO, C. ; GRISOLI, P. ; CARAMELLA, C.: "Thermally sensitive gels based on chitosan derivatives for the treatment of oral mucositis", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, vol. 74, no. 2, 1 February 2010 (2010-02-01), NL , pages 248 - 254, XP026935241, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2009.10.003 *

Similar Documents

Publication Publication Date Title
ES2308045T3 (es) Composiciones fungicidas, lubricantes de calentamiento y no irritantes en la forma de un gel.
US9114156B2 (en) Enhanced antimicrobial skin preparation
KR101792200B1 (ko) 열감응성 겔 마취제 조성물
FI119498B (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
TW473386B (en) New pharmaceutical composition with anaesthetic effect
FI78235B (fi) Foerfarande foer framstaellning av en topisk anti-inflammatorisk komposition i gelsalvaform.
JP2002514220A (ja) 熱傷処置および感染防止のための局部スプレー
JP5740393B2 (ja) 皮膚および爪の真菌感染症の局所治療に適した組成物
HU220864B1 (en) Reversible, thermally gelling water-base medicinal compositions
JPH04210907A (ja) 局部塗付用組成物
JPH07508975A (ja) 生体接着性水性鉱油エマルション軟膏基剤，それからなる局所医薬組成物及び創傷治癒におけるその使用
EP1620069B1 (fr) Compositions lubrifiantes, fongicides, non-irritatives et chauffantes sous forme de gel
KR20170036058A (ko) 코 적용을 위한 시네올-함유 조성물
JP4473938B1 (ja) 口腔用軟膏
JP2006519847A (ja) ゲル状組成物及び膣感染症治療のための方法
CN105079858A (zh) 一种伤口杀菌修复液体敷料及其制法
JP2003128586A (ja) 物理的に安定で噴霧可能なゲル組成物
CN107668062B (zh) 基于透明质酸的奥兰西丁水溶液及其制备方法和应用
JP2006519272A (ja) ポロキサマーエマルジョン製剤
WO2024118019A1 (fr) Formulations de gel thermosensibles dermiques pour le traitement d'un oedème lié à une inflammation et de diverses douleurs
CN100391449C (zh) 氯胺t在治疗皮肤、粘膜、器官和组织之疾病中的应用
JP5494112B2 (ja) 口腔用軟膏
TR2022018327A1 (tr) Enflamasyona bağli ödem ve çeşi̇tli̇ ağrilarin tedavi̇si̇ i̇çi̇n dermal termosensitiv jel formülasyonlari
CN107646862B (zh) 基于抗坏血酸的奥兰西丁水溶液及其制备方法和应用
WO2021101777A1 (fr) Formulations topiques à solidification spontanée avec anesthésique local

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23898458

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载